CY1124554T1 - Μεθοδοι και συνθεσεις για διεγερση του εντερικου εντεροενδοκρινους συστηματος για θεραπεια ασθενειων ή καταστασεων που σχετιζονται προς αυτο - Google Patents
Μεθοδοι και συνθεσεις για διεγερση του εντερικου εντεροενδοκρινους συστηματος για θεραπεια ασθενειων ή καταστασεων που σχετιζονται προς αυτοInfo
- Publication number
- CY1124554T1 CY1124554T1 CY20211100573T CY211100573T CY1124554T1 CY 1124554 T1 CY1124554 T1 CY 1124554T1 CY 20211100573 T CY20211100573 T CY 20211100573T CY 211100573 T CY211100573 T CY 211100573T CY 1124554 T1 CY1124554 T1 CY 1124554T1
- Authority
- CY
- Cyprus
- Prior art keywords
- stimulating
- methods
- diseases
- compositions
- treatment
- Prior art date
Links
- 230000004936 stimulating effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 210000000750 endocrine system Anatomy 0.000 title 1
- 230000000968 intestinal effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 abstract 1
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 abstract 1
- 241000251778 Squalus acanthias Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000000105 enteric nervous system Anatomy 0.000 abstract 1
- 229950001248 squalamine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462015657P | 2014-06-23 | 2014-06-23 | |
| US14/329,627 US10040817B2 (en) | 2013-10-03 | 2014-07-11 | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
| PCT/US2015/036935 WO2015200195A1 (en) | 2014-06-23 | 2015-06-22 | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124554T1 true CY1124554T1 (el) | 2022-07-22 |
Family
ID=54869043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100573T CY1124554T1 (el) | 2014-06-23 | 2021-06-28 | Μεθοδοι και συνθεσεις για διεγερση του εντερικου εντεροενδοκρινους συστηματος για θεραπεια ασθενειων ή καταστασεων που σχετιζονται προς αυτο |
Country Status (19)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10040817B2 (en) | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
| US20160058730A1 (en) * | 2014-08-29 | 2016-03-03 | Cadila Healthcare Limited | Pharmaceutical compositions of teriflunomide |
| WO2018222665A1 (en) * | 2017-05-31 | 2018-12-06 | Enterin Laboratories, Inc. | Methods and compositions for preventing or treating inflammatory diseases |
| US11083735B2 (en) * | 2017-09-08 | 2021-08-10 | Enterin, Inc. | Methods for treating sleep disorders, sleep disturbances, and related symptoms using aminosterol compositions |
| WO2019089365A1 (en) * | 2017-10-30 | 2019-05-09 | Enterin Laboratories, Inc. | New squalamine solid forms and methods of making the same |
| CA3094977A1 (en) * | 2018-03-27 | 2019-10-03 | Enterin, Inc. | Methods and compositions for treating hallucinations and conditions related to the same |
| MX2020013614A (es) * | 2018-06-13 | 2021-05-27 | Enterin Inc | Métodos y composiciones para tratar y/o prevenir el progreso y/o inicio de neurodegeneración relacionada con la edad. |
| US20210315907A1 (en) * | 2018-08-03 | 2021-10-14 | Enterin, Inc, | Compositions and methods for treating brain-gut disorders |
| US20210260078A1 (en) * | 2018-08-03 | 2021-08-26 | Philadelphia | Low dosage intranasal aminosterol dosage forms and methods of using the same |
| US11464789B2 (en) | 2018-08-03 | 2022-10-11 | Enterin, Inc. | Aminosterol compositions and methods of using the same for treating schizophrenia |
| EP3829587A4 (en) * | 2018-08-03 | 2022-07-20 | Enterin, Inc. | COMPOSITIONS AND METHODS FOR TREATING GUT-BRAIN AXIS DISORDERS |
| EP4427738A3 (en) * | 2019-08-02 | 2024-12-04 | Enterin, Inc. | Dosing protocols and regimens for aminosterol treatment |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5192756A (en) | 1992-03-18 | 1993-03-09 | The Children's Hospital Of Pennsylvania | Aminosterol antibiotic |
| US5352682A (en) | 1993-03-08 | 1994-10-04 | Digestive Care Inc. | Compositions containing salts of bile acid-aminosalicylate conjugates |
| DE69412596T2 (de) | 1993-03-10 | 1999-03-04 | Magainin Pharmaceuticals Inc., Plymouth Meeting, Pa. | Steroidderivate, pharmazeutische zusammensetzungen die sie enthalten und ihre verwendung als antibiotika oder desinfektionsmittel |
| US5856535A (en) | 1994-08-18 | 1999-01-05 | Magainin Pharmaceuticals, Inc. | Aminosterol ester compounds |
| US5840740A (en) | 1995-06-07 | 1998-11-24 | Magainin Pharmaceuticals Inc. | Aminosterol compounds and a method of treating infection using the aminosterol compounds |
| AU3512595A (en) | 1994-09-13 | 1996-03-29 | Magainin Pharmaceuticals, Inc. | Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds |
| US5834453A (en) | 1995-05-30 | 1998-11-10 | Lehigh University | Methods for the manufacture and use of antimicrobial sterol conjugates |
| US5847172A (en) | 1995-06-07 | 1998-12-08 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| US6143738A (en) | 1995-06-07 | 2000-11-07 | Magainin Pharmaceuticals, Inc. | Therapeutic uses for an aminosterol compound |
| JP4104164B2 (ja) * | 1995-06-07 | 2008-06-18 | ジェネーラ コーポレーション | ナトリウム／プロトン交換体（ｎｈｅ）の阻害剤として有用なアミノステロール化合物、同阻害剤を使用する薬学的方法および組成物、ならびに化合物のｎｈｅ阻害効果を評価する方法 |
| US5795885A (en) | 1995-06-07 | 1998-08-18 | Magainin Pharmaceuticals Inc. | Method of inhibiting profileration of cells by administering an aminosterol compound |
| US5840936A (en) | 1995-06-07 | 1998-11-24 | Magainin Pharmaceuticals Inc. | Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE) |
| US5763430A (en) | 1995-06-07 | 1998-06-09 | Magainin Pharmaceuticals Inc. | Method of treating a viral infection by administering a steroid compound |
| US5792635A (en) | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| US5874597A (en) | 1995-06-07 | 1999-02-23 | Magainin Pharmaceuticals, Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| US5994336A (en) | 1995-06-07 | 1999-11-30 | Magainin Pharmaceuticals Inc. | Method of inhibiting proliferation of cells by administering an aminosterol compound |
| US5744453A (en) | 1996-01-05 | 1998-04-28 | Mintz; Clifford S. | Polyamine conjugates for treatment of infection |
| US6596712B2 (en) | 1996-04-26 | 2003-07-22 | Genaera Corporation | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
| US6147060A (en) | 1996-04-26 | 2000-11-14 | Magainin Pharmaceuticals | Treatment of carcinomas using squalamine in combination with other anti-cancer agents |
| AU726909B2 (en) | 1996-05-17 | 2000-11-23 | Magainin Pharmaceuticals, Inc. | Therapeutic uses for an aminosterol compound |
| US7410959B1 (en) * | 2000-07-13 | 2008-08-12 | Genaera Corporation | Therapeutic uses for aminosterol compounds |
| WO1998019682A1 (en) | 1996-11-01 | 1998-05-14 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and uses therefor |
| CA2339174C (en) | 1998-08-12 | 2009-01-06 | Magainin Pharmaceuticals, Inc. | Aminosterol compounds and uses thereof |
| US6288089B1 (en) * | 1998-12-21 | 2001-09-11 | Michael Zawada | Use of kinase inhibitors for treating neurodegenerative diseases |
| AU2002243204A1 (en) * | 2000-10-06 | 2002-06-11 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
| EP1361847A2 (en) | 2000-10-06 | 2003-11-19 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
| PT2260850T (pt) * | 2002-01-28 | 2018-10-24 | Kyowa Hakko Kogyo Kk | Antagonistas do recetor de a2a para utilização no tratamento de distúrbios de movimento |
| WO2004034963A2 (en) | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| ES2727284T3 (es) | 2005-04-25 | 2019-10-15 | Enterin Inc | Formas de sales polimórficas y amorfas de dilactato de escualamina |
| CA2985271A1 (en) * | 2007-09-06 | 2009-03-12 | Ohr Pharmaceutical, Inc. | A method for treating diabetes |
| US8247435B2 (en) * | 2009-02-19 | 2012-08-21 | Thornthwaite Jerry T | Formulations for treating human and animal diseases |
| US8729058B2 (en) | 2009-10-27 | 2014-05-20 | Michael Zasloff | Methods and compositions for treating and preventing viral infections |
| WO2011066260A2 (en) | 2009-11-25 | 2011-06-03 | Michael Zasloff | Formulations comprising aminosterols |
| CA2870671C (en) | 2012-04-20 | 2020-05-12 | Ohr Pharmaceutical Inc. | Aminosteroids for the treatment of a ptp1b associated disease |
| CN102813659A (zh) * | 2012-08-21 | 2012-12-12 | 贵阳中医学院 | 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途 |
| CA2896073C (en) | 2012-12-20 | 2021-10-19 | Mount Desert Island Biological Laboratory | Stimulation and enhancement of regeneration of tissues |
| US10040817B2 (en) | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
-
2014
- 2014-07-11 US US14/329,627 patent/US10040817B2/en active Active
-
2015
- 2015-06-22 CA CA2951720A patent/CA2951720C/en active Active
- 2015-06-22 BR BR112016029917A patent/BR112016029917A2/pt not_active Application Discontinuation
- 2015-06-22 WO PCT/US2015/036935 patent/WO2015200195A1/en active Application Filing
- 2015-06-22 EP EP15811714.3A patent/EP3157531B1/en active Active
- 2015-06-22 HR HRP20211005TT patent/HRP20211005T1/hr unknown
- 2015-06-22 CN CN201580033333.7A patent/CN106535902B/zh active Active
- 2015-06-22 JP JP2016574402A patent/JP6692300B2/ja active Active
- 2015-06-22 DK DK15811714.3T patent/DK3157531T3/da active
- 2015-06-22 SI SI201531637T patent/SI3157531T1/sl unknown
- 2015-06-22 CN CN202110489234.7A patent/CN113559108A/zh active Pending
- 2015-06-22 RS RS20210819A patent/RS62064B1/sr unknown
- 2015-06-22 LT LTEP15811714.3T patent/LT3157531T/lt unknown
- 2015-06-22 ES ES15811714T patent/ES2878077T3/es active Active
- 2015-06-22 HU HUE15811714A patent/HUE054828T2/hu unknown
- 2015-06-22 PT PT158117143T patent/PT3157531T/pt unknown
- 2015-06-22 SM SM20210373T patent/SMT202100373T1/it unknown
- 2015-06-22 PL PL15811714T patent/PL3157531T3/pl unknown
- 2015-06-22 MX MX2016017368A patent/MX382442B/es unknown
-
2016
- 2016-12-20 MX MX2021005489A patent/MX2021005489A/es unknown
-
2017
- 2017-05-24 US US15/604,527 patent/US10208080B2/en active Active
- 2017-05-24 US US15/604,452 patent/US10196420B2/en active Active
- 2017-05-24 US US15/604,489 patent/US10208079B2/en active Active
-
2018
- 2018-07-13 US US16/035,537 patent/US10633413B2/en active Active
- 2018-07-18 US US16/039,294 patent/US11440936B2/en active Active
- 2018-12-13 US US16/219,848 patent/US10975116B2/en active Active
- 2018-12-13 US US16/219,879 patent/US20190185513A1/en not_active Abandoned
- 2018-12-14 US US16/220,860 patent/US20190194244A1/en not_active Abandoned
-
2020
- 2020-01-21 JP JP2020007206A patent/JP7010979B2/ja active Active
-
2021
- 2021-06-28 CY CY20211100573T patent/CY1124554T1/el unknown
-
2022
- 2022-04-01 US US17/711,891 patent/US20220220148A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124554T1 (el) | Μεθοδοι και συνθεσεις για διεγερση του εντερικου εντεροενδοκρινους συστηματος για θεραπεια ασθενειων ή καταστασεων που σχετιζονται προς αυτο | |
| EP3618829A4 (en) | QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER ASSOCIATED DISORDERS | |
| IL290980A (en) | Rna for the treatment of autoimmune diseases | |
| EP3259017A4 (en) | Nerve stimulation for treatment of diseases and disorders | |
| EA201791095A1 (ru) | Способ лечения рака | |
| EA201790650A1 (ru) | Лекарственная форма и способы применения абиратерона ацетата | |
| IL320533A (en) | Methods and compositions for treating disorders and diseases involving RDH12 | |
| IL262713A (en) | Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases | |
| MA40406A (fr) | Procédés et compositions de diagnostic et de traitement des maladies inflammatoires chroniques de l'intestin | |
| PH12018502154A1 (en) | Methods of treating ocular conditions | |
| ZA201703467B (en) | Methods of treating ocular conditions | |
| EP3406255C0 (en) | GRAFT MATERIAL FOR HEART DISEASE THERAPY | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| IL259710A (en) | Preparations and methods for the treatment of Davidson's disease (microvillus inclusion disease) and related diseases | |
| IL280952A (en) | Methods and drug compounds for the treatment of ophthalmic diseases | |
| IL272604A (en) | Preparations for the treatment of intestinal infections | |
| EP3500591A4 (en) | COMPOSITIONS AND METHODS FOR TREATING BONE-ASSOCIATED DISEASES | |
| EP3402531A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | |
| IT201800011030A1 (it) | Metodo per la determinazione quali-quantitativa del microbiota intestinale | |
| HK40008797B (en) | Compositions and methods for treatment of bone associated diseases | |
| HK1236807A1 (en) | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same | |
| HK40013460B (en) | Methods and compositions for treatment of disorders and diseases involving rdh12 | |
| HK40008876A (en) | Methods and compositions for treatment of disorders and diseases involving rdh12 | |
| HK40008112A (en) | Compositions and methods for treatment of cardiac diseases |